Imatinib mesylate__Kinase inhibitor AF38470
Product Name
Imatinib mesylate
Description
Kinase inhibitor
Purity
>98% (HPLC)
CAS No.
152459-95-5
Molecular Formula
C30H35N7O4S
Molecular Weight
589.7
Storage Temperature
-20ºC
Shipping Temperature
Shipped Ambient
Product Type
Inhibitor
Solubility
Soluble H2O: soluble10 mg/ml, clear
Source
Synthetic
Appearance
White to beige solid
SMILES
C5=C(C1=CN=CC=C1)N=C(NC2=C(C=CC(=C2)NC(C3=CC=C(C=C3)CN4CCN(CC4)C)=O)C)N=C5
InChI
InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)
InChIKey
KTUFNOKKBVMGRW-UHFFFAOYSA-N
Safety Phrases
Classification:
Acute toxicity, Oral (Category 4), H302
Safety Phrases:
S22 – Do not breathe dust.
S24/25 – Avoid contact with skin and eyes.
S36/37/39 – Wear suitable protective clothing, gloves and eye/face protection.
Hazard statements:
H302 Harmful if swallowed.
Precautionary statements:
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P301 + P312 IF SWALLOWED: Call a POISON CENTER or doctor/ physician if you feel unwell.
P330 Rinse mouth.
P501 Dispose of contents/ container to an approved waste disposal plant.
Cite This Product
Imatinib mesylate (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-453)
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19132983
Alternative Names
4-(4-Methyl-1-piperazinyl)methyl-N-4-methyl-3-4-(3-pyridinyl)-2-pyrimidinylamino-phenylbenzamide methanesulfonate, 4-(4-Methylpiperazin-1-yl)methyl-N-(4-methyl-3-{4-(pyridin-3-yl)pyrimidin-2-ylamino}phenyl)benzamide mesylate, CGP 57148, Genfatinib, Glivec, Imatinib methanesulfonate, STI-571
Research Areas
Cancer, Apoptosis, Cancer Growth Inhibitors, Cell Signaling, Tyrosine Kinase Inhibitors
PubChem ID
5291
Scientific Background
Imatinib mesylate is a tyrosine kinase inhibitor. It specifically inhibits Bcr-Abl tyrosine kinase, and receptor tyrosine kinases encoded by c-kit and platelet-derived growth factor receptor (PDGFR) oncogenes.
References
1. Kantarjian H., et al. (2002). N.E. J. Med. 346(9): 645–652.
Kinase inhibitor
Acute toxicity, Oral (Category 4), H302
Safety Phrases:
S22 – Do not breathe dust.
S24/25 – Avoid contact with skin and eyes.
S36/37/39 – Wear suitable protective clothing, gloves and eye/face protection.
Hazard statements:
H302 Harmful if swallowed.
Precautionary statements:
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P301 + P312 IF SWALLOWED: Call a POISON CENTER or doctor/ physician if you feel unwell.
P330 Rinse mouth.
P501 Dispose of contents/ container to an approved waste disposal plant.